These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10839461)

  • 1. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
    Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
    Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
    Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
    Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
    Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
    J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
    J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.
    Klein SI; Czekaj M; Gardner CJ; Guertin KR; Cheney DL; Spada AP; Bolton SA; Brown K; Colussi D; Heran CL; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1998 Feb; 41(4):437-50. PubMed ID: 9484495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
    Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.
    Lee SL; Alexander RS; Smallwood A; Trievel R; Mersinger L; Weber PC; Kettner C
    Biochemistry; 1997 Oct; 36(43):13180-6. PubMed ID: 9341205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
    J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
    Katakura S; Nagahara T; Hara T; Iwamoto M
    Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-crystal structure and inhibition of factor Xa by PD0313052 identifies structurally stabilized active site residues of factor Xa and prothrombinase.
    Gould WR; Cladera E; Harris MS; Zhang E; Narasimhan L; Thorn JM; Leadley RJ
    Biochemistry; 2005 Jul; 44(26):9280-9. PubMed ID: 15981994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity.
    Koepke J; Ermler U; Warkentin E; Wenzl G; Flecker P
    J Mol Biol; 2000 May; 298(3):477-91. PubMed ID: 10772864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
    J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.